Effect of Omeprazole on Pharmacokinetics of SHR2554 in Healthy Subjects
The study aimed to assess the effects of omeprazole on single-dose SHR2554 in healthy subjects, exploring the pharmacokinetic changes of SHR2554 and ensuring the safety when SHR2554 is co-administered with omeprazole.
Malignant Tumor
DRUG: SHR2554 tablet dosing|DRUG: Omeprazole tablet dosing
Cmax of SHR2554: Rate and extent of absorption of SHR2554 following single oral doses of SHR2554 by assessment of maximum plasma concentration., PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose|AUC0-t of SHR2554: Assessment of the PK of SHR2554 using area under the plasma concentration curve from zero extrapolated to o the time of the last quantifiable concentration., PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose|AUC0-∞ of SHR2554: Assessment of the PK of SHR2554 using area under the plasma concentration-time curve from zero to infinity., PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose|Tmax of SHR2554: Assessment of the PK of SHR2554 using time to reach maximum plasma concentration., PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose|t1/2 of SHR2554: Assessment of the PK of SHR2554 using the terminal half-life., PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose|CL/F of SHR2554: Assessment of the PK of SHR2554 using the apparent plasma clearance., PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose|Vz/F of SHR2554: Assessment of the PK of AZD9291 using the apparent volume of distribution., PK samples collected in both period 1 and 2 at pre-dose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, and 48 hours post SHR2554 dose
Incidence and severity of adverse events/serious adverse events, From Day 1 to Day 15|Change in Fridericia-corrected QTc interval (QTcF) relative to baseline (ΔQTcF), ECG samples collected in period 1 at pre-dose,1, 2, 3, 4, 6, 8, 12, and 24 hours post SHR2554 dose
The study aimed to assess the effects of omeprazole on single-dose SHR2554 in healthy subjects, exploring the pharmacokinetic changes of SHR2554 and ensuring the safety when SHR2554 is co-administered with omeprazole.